[CAS NO. 120-97-8]  Dichlorphenamide

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [120-97-8]

Catalog
HY-B0397
Brand
MCE
CAS
120-97-8

DESCRIPTION [120-97-8]

Overview

MDLMFCD00148948
Molecular Weight305.16
Molecular FormulaC6H6Cl2N2O4S2
SMILESO=S(C1=CC(Cl)=C(Cl)C(S(=O)(N)=O)=C1)(N)=O

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE


Summary

Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor . Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research [1] .


In Vivo

Dichlorphenamide can reduce IOP locally in male albino rabbits [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male albino rabbits (approximately 2.5 kg)
Dosage: 50 μL 10% aqueous solutions of dichlorphenamide sodium or 2 mg/kg, 6 mg/kg
Administration: Eye drop of 50 μL or Oral gavage of 2 mg/kg or 6 mg/kg, 5 hours
Result: Showed significant decrease in IOP at 30 min by instilling into eyes and decrease in IOP only at 1 h by orally after drug administration, and demonstrated that drug levels were significantly higher in the iris ciliary body and lower in the serum by instilling compared to oral administration.

Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT00494507 University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)
Hyperkalemic Periodic Paralysis|Hypokalemic Periodic Paralysis
June 2007 Phase 3
NCT00004802 National Center for Research Resources (NCRR)|Ohio State University|Office of Rare Diseases (ORD)
Paralysis, Hyperkalemic Periodic|Hypokalemic Periodic Paralysis|Paramyotonia Congenita
June 1992 Phase 3

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 327.70 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2770 mL 16.3848 mL 32.7697 mL
5 mM 0.6554 mL 3.2770 mL 6.5539 mL
10 mM 0.3277 mL 1.6385 mL 3.2770 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (8.19 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (8.19 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.19 mM); Clear solution

* All of the co-solvents are available by MCE.


Synonyms

1,3-Benzenedisulfonamide, 4,5-dichloro-
m-Benzenedisulfonamide, 4,5-dichloro-
4,5-Dichloro-1,3-benzenedisulfonamide
Daranide
Dichlofenamide
4,5-Dichloro-m-benzenedisulfonamide
4,5-Dichloro-1,3-disulfamoylbenzene
Dichlorophenamide
3,4-Dichloro-5-sulfamylbenzenesulfonamide
Dichlorphenamide
Oratrol
1,3-Disulfamyl-4,5-dichlorobenzene
Antidrasi
1,3-Disulfamoyl-4,5-dichlorobenzene
Daramide
Diclofenamid
Glaucol
Diclofenamide
CB 8000
Keveyis